Arcutis Biotherapeutics Management
Management criteria checks 3/4
Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 8.92 years. total yearly compensation is $4.94M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.57% of the company’s shares, worth $9.94M. The average tenure of the management team and the board of directors is 2.9 years and 4.3 years respectively.
Key information
Frank Watanabe
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 12.8% |
| CEO tenure | 8.9yrs |
| CEO ownership | 0.6% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump
Nov 27
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$196m |
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$5m | US$634k | -US$262m |
| Sep 30 2023 | n/a | n/a | -US$268m |
| Jun 30 2023 | n/a | n/a | -US$331m |
| Mar 31 2023 | n/a | n/a | -US$327m |
| Dec 31 2022 | US$5m | US$590k | -US$311m |
| Sep 30 2022 | n/a | n/a | -US$311m |
| Jun 30 2022 | n/a | n/a | -US$260m |
| Mar 31 2022 | n/a | n/a | -US$235m |
| Dec 31 2021 | US$4m | US$525k | -US$206m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$150m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$3m | US$442k | -US$136m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$63m |
| Dec 31 2019 | US$1m | US$390k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$634k | US$327k | -US$19m |
Compensation vs Market: Frank's total compensation ($USD4.94M) is about average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Watanabe (56 yo)
8.9yrs
Tenure
US$4,935,266
Compensation
Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.9yrs | US$4.94m | 0.57% $ 9.9m | |
| Co-Founder & Independent Director | no data | US$153.74k | 0.77% $ 13.5m | |
| Executive VP & Chief Medical Officer | 4.3yrs | US$1.67m | 0.11% $ 1.9m | |
| Executive VP & Chief Commercial Officer | 1.3yrs | US$2.03m | no data | |
| Senior VP & Chief Financial Officer | less than a year | no data | 0.041% $ 725.1k | |
| Chief Digital & Technology Officer | 3.2yrs | no data | no data | |
| VP and Chief Compliance Officer & Privacy Officer | 3.8yrs | no data | no data | |
| Senior VP | 2.9yrs | US$5.14m | 0.048% $ 839.2k | |
| Head of Corporate Communications | 3.3yrs | no data | no data | |
| Senior Vice President of Sales | 1.9yrs | no data | no data | |
| Vice President of Marketing | less than a year | no data | no data | |
| Senior VP & Chief Human Resources Officer | 2.8yrs | no data | no data |
2.9yrs
Average Tenure
56yo
Average Age
Experienced Management: ARQT's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.9yrs | US$4.94m | 0.57% $ 9.9m | |
| Co-Founder & Independent Director | 8.7yrs | US$153.74k | 0.77% $ 13.5m | |
| Board Member | 8.7yrs | US$181.24k | 0.028% $ 485.3k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Chairman of the Board | 3.3yrs | US$146.24k | 0.0089% $ 156.5k | |
| Independent Director | 4.1yrs | US$148.74k | 0% $ 0 | |
| Director | 4.3yrs | US$144.24k | 0.13% $ 2.3m | |
| Independent Director | 3.5yrs | US$163.74k | 0.0077% $ 134.7k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ARQT's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 14:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arcutis Biotherapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Chris Shibutani | Goldman Sachs |
| Seamus Fernandez | Guggenheim Securities, LLC |